Literature DB >> 14726994

Effects of acute and chronic clozapine on D-amphetamine-induced disruption of auditory gating in the rat.

Brian Joy1, Robert P McMahon, Paul D Shepard.   

Abstract

RATIONALE: Auditory gating deficits observed in patients with schizophrenia have been modeled in animals administered the indirect-acting monoaminergic agonist, D-amphetamine (AMPH). The atypical antipsychotic drug clozapine (CLOZ) reverses the disruption of auditory gating in schizophrenic patients. However, its effects on psychostimulant-induced deficits in animals have yet to be assessed.
OBJECTIVES: In the present series of experiments, an auditory evoked potential paradigm was used to: (a) confirm the ability of AMPH to alter auditory gating in the anesthetized rat, (b) specify the nature of the accompanying change(s) in evoked potential waveforms and (c) determine the effects of CLOZ administration on AMPH-induced alterations in auditory gating.
METHODS: We compared the effects of acute (5 mg/kg, i.p.) and chronic (28 days, 0.5 mg/ml in drinking water) CLOZ on AMPH-induced (1.8 mg/kg, i.p.) alterations in evoked potentials recorded in the hippocampus of anesthetized rats during presentation of a pair of identical tones. Gating was assessed by comparing the amplitude of conditioning and test responses in CLOZ and AMPH-treated rats.
RESULTS: The ratio of test to conditioning response amplitude (T/C ratio) was not altered by vehicle or CLOZ alone. However, T/C ratio was significantly increased following AMPH due to suppression of the conditioning response. Acute but not chronic CLOZ attenuated but did not prevent the increase in T/C ratio.
CONCLUSIONS: Qualitative differences between the idiopathic gating deficits observed in schizophrenic patients and AMPH-induced increases in T/C ratio in animals limit this models utility as a means of evaluating the ability of atypical antipsychotic drugs to restore normal sensory gating.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14726994     DOI: 10.1007/s00213-003-1731-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  51 in total

1.  Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.

Authors:  S Kapur; P Seeman
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol.

Authors:  Bob Oranje; Christine C Gispen-de Wied; Marinus Nicholaas Verbaten; René S Kahn
Journal:  Biol Psychiatry       Date:  2002-11-01       Impact factor: 13.382

3.  Effects of P50 temporal variability on sensory gating in schizophrenia.

Authors:  Y Jin; S G Potkin; J V Patterson; C A Sandman; W P Hetrick; W E Bunney
Journal:  Psychiatry Res       Date:  1997-05-05       Impact factor: 3.222

4.  Dopaminergic and noradrenergic modulation of amphetamine-induced changes in auditory gating.

Authors:  K E Stevens; L L Fuller; G M Rose
Journal:  Brain Res       Date:  1991-07-26       Impact factor: 3.252

5.  Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia.

Authors:  C M Cullum; J G Harris; M C Waldo; E Smernoff; A Madison; H T Nagamoto; J Griffith; L E Adler; R Freedman
Journal:  Schizophr Res       Date:  1993-08       Impact factor: 4.939

6.  Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats.

Authors:  N M de Bruin; B A Ellenbroek; A R Cools; A M Coenen; E L van Luijtelaar
Journal:  Psychopharmacology (Berl)       Date:  1999-02       Impact factor: 4.530

7.  The dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration.

Authors:  X M Gao; T Hashimoto; T B Cooper; C A Tamminga
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 8.  Information processing and attention dysfunctions in schizophrenia.

Authors:  D L Braff
Journal:  Schizophr Bull       Date:  1993       Impact factor: 9.306

Review 9.  Schizophrenia, sensory gating, and nicotinic receptors.

Authors:  L E Adler; A Olincy; M Waldo; J G Harris; J Griffith; K Stevens; K Flach; H Nagamoto; P Bickford; S Leonard; R Freedman
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

10.  Neurobiological studies of sensory gating in schizophrenia.

Authors:  R Freedman; L E Adler; G A Gerhardt; M Waldo; N Baker; G M Rose; C Drebing; H Nagamoto; P Bickford-Wimer; R Franks
Journal:  Schizophr Bull       Date:  1987       Impact factor: 9.306

View more
  5 in total

1.  Auditory sensory gating in the neonatal ventral hippocampal lesion model of schizophrenia.

Authors:  Jenifer L Vohs; R Andrew Chambers; Giri P Krishnan; Brian F O'Donnell; William P Hetrick; Samuel T Kaiser; Sarah Berg; Sandra L Morzorati
Journal:  Neuropsychobiology       Date:  2009-08-14       Impact factor: 2.328

2.  Sensory gating and its modulation by cannabinoids: electrophysiological, computational and mathematical analysis.

Authors:  Margarita Zachariou; Dilshani W N Dissanayake; Stephen Coombes; Markus R Owen; Robert Mason
Journal:  Cogn Neurodyn       Date:  2008-04-23       Impact factor: 5.082

3.  Dose-response characteristics of methylphenidate on locomotor behavior and on sensory evoked potentials recorded from the VTA, NAc, and PFC in freely behaving rats.

Authors:  Pamela B Yang; Alan C Swann; Nachum Dafny
Journal:  Behav Brain Funct       Date:  2006-01-17       Impact factor: 3.759

Review 4.  Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.

Authors:  J Smucny; K E Stevens; A Olincy; J R Tregellas
Journal:  Transl Psychiatry       Date:  2015-06-23       Impact factor: 6.222

5.  Modulation of mGlu2 Receptors, but Not PDE10A Inhibition Normalizes Pharmacologically-Induced Deviance in Auditory Evoked Potentials and Oscillations in Conscious Rats.

Authors:  Abdallah Ahnaou; Ria Biermans; Wilhelmus H Drinkenburg
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.